ArriVent BioPharma Inc. C... (AVBP)
ArriVent BioPharma Common Stock Statistics
Share Statistics
ArriVent BioPharma Common Stock has 34.02M shares outstanding. The number of shares has increased by 5.45% in one year.
| Shares Outstanding | 34.02M |
| Shares Change (YoY) | 5.45% |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.43M |
| Failed to Deliver (FTD) Shares | 396 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 3.54M, so 10.49% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short % of Shares Out | 10.49% |
| Short % of Float | 18.13% |
| Short Ratio (days to cover) | 24.21 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -8.24. ArriVent BioPharma Common Stock's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -8.24 |
| PS Ratio | 0 |
| Forward PS | 2.2 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ArriVent BioPharma Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.14, with a Debt / Equity ratio of 0.
| Current Ratio | 13.14 |
| Quick Ratio | 13.14 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.07 |
| Cash Flow / Debt | -398.93 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is -28.93%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | -28.93% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,333,326.92 |
| Employee Count | 52 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 6.56% in the last 52 weeks. The beta is 1.02, so ArriVent BioPharma Common Stock's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | 6.56% |
| 50-Day Moving Average | 24.94 |
| 200-Day Moving Average | 24.86 |
| Relative Strength Index (RSI) | 24.41 |
| Average Volume (20 Days) | 168.63K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -74.59M |
| Net Income | -69.33M |
| EBITDA | -74.59M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.17 |
Balance Sheet
The company has 74.29M in cash and 176K in debt, giving a net cash position of 74.12M.
| Cash & Cash Equivalents | 74.29M |
| Total Debt | 176K |
| Net Cash | 74.12M |
| Retained Earnings | -238.33M |
| Total Assets | 274.94M |
| Working Capital | 209.71M |
Cash Flow
In the last 12 months, operating cash flow was -70.21M and capital expenditures 0, giving a free cash flow of -70.21M.
| Operating Cash Flow | -70.21M |
| Capital Expenditures | 0 |
| Free Cash Flow | -70.21M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.14% |
| FCF Yield | -10.6% |
Analyst Forecast
The average price target for AVBP is $38, which is 95.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 95.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 21.96 |
| Piotroski F-Score | 1 |